Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Randomized, Double-blind Trial of BMF-219 Compared to Placebo in Participants with Type 1 Diabetes Mellitus

Next Previous
Search
Trial Profile

Phase 2 Randomized, Double-blind Trial of BMF-219 Compared to Placebo in Participants with Type 1 Diabetes Mellitus

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Icovamenib (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms COVALENT-112
  • Sponsors Biomea Fusion

    • Most Recent Events

    • 31 Mar 2025 According to a Biomea Fusion media release, Initial open label data from the Phase II study is expected in the second half of 2025.
    • 17 Dec 2024 According to Biomea Fusion media release, the company It had a more profound impact on the ongoing Phase II COVALENT -112 study in type 1 diabetes, where over 90% of the targeted patient population were not able to complete dosing due to the clinical hold and We are therefore company planning to continue the enrollment in COVALENT-112 so we can provide a more complete update in this patient population in 2025.
    • 18 Nov 2024 According to Biomea Fusion media release, the company to present trial in progress poster reporting the Phase II design of COVALENT-112 at the ATTD-Asia.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top